	US 12,414,938 B2
	Ophthalmic topical cream compositions and methods
James Jane-Guo Shiah, Irvine, CA (US); Xiaojun Michael Liu, Lake Forest, CA (US); and Gabriella Szekely, Irvine, CA (US)
Assigned to GLAUKOS CORPORATION, Aliso Viejo, CA (US)
Filed by GLAUKOS CORPORATION, Aliso Viejo, CA (US)
Filed on Apr. 20, 2023, as Appl. No. 18/304,263.
Claims priority of provisional application 63/363,356, filed on Apr. 21, 2022.
Prior Publication US 2023/0381145 A1, Nov. 30, 2023
Int. Cl. A61K 31/4178 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01)

CPC A61K 31/4178 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01)]

19 Claims

1. An ophthalmic therapeutic treatment composition, comprising:

a topical cream comprising 0.05% to 8% (w/w) of a crosslinked acrylic acid polymer and 0.025% to 8% (w/w) of an acrylamide/sodium acryloyldimethyl taurate copolymer; and

0.001% to 10% (w/w) of an active pharmaceutical ingredient (API) dispersed in the topical cream;

wherein the pH of the ophthalmic therapeutic treatment composition is about 3.5; and

wherein the ophthalmic therapeutic treatment composition is formulated for application to an outer surface of an eyelid to deliver the API into an eye.